Physician profile
Scott J Lance
NPI 1467462101
$9,837.07
in general payments reported to CMS, 2019-2025
23 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $1,394 · 2021: $1,162 · 2022: $1,849 · 2023: $1,309 · 2024: $1,569 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,320 · Education: $6.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,319.53 |
| Education | $6.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,443.95 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $1,129.31 | 2019-2022 | |
| Abbvie INC. | $1,036.06 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $696.36 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alkermes, INC. | $691.60 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $682.12 | 2020-2025 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $575.05 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $561.87 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $547.47 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $538.20 | 2021-2025 | Caplyta |
| Lundbeck LLC | $528.89 | 2019-2025 | Rexulti |
| Allergan, INC. | $351.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $280.80 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Bausch Health US, LLC | $280.77 | 2019-2023 | Aplenzin, Wellbutrin |
| Eisai INC. | $119.56 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $83.00 | 2021-2022 | |
| Almatica Pharma LLC | $78.13 | 2021-2023 | Loreev Xr |
| Tris Pharma INC | $47.20 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $43.18 | 2022-2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $34.46 | 2025 | Cobenfy |
| Indivior INC. | $34.19 | 2022 | |
| Idorsia Pharmaceuticals US INC | $28.37 | 2023 | Quviviq |
| Astellas Pharma US INC | $24.73 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.